The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant therapy plus additional post-surgical adjuvant therapy (NAPAT) is projected to lower US breast-cancer mortality to 23.0/100,000 by 2030, versus No NAPAT.
- Why it matters: The approach could improve outcomes for women with residual disease, but its population-level benefit in the US has not been quantified.
- What they did: Six CISNET models simulated US female birth-cohorts eligible for chemotherapy, projecting 2018–2030 mortality using trial and registry-derived screening and treatment inputs, with post-2018 trends held constant.
- The result: NAPAT predicts a 10.5% (6.5%–14.0%) mortality reduction overall by 2030, with larger decreases for triple negative (30.7%) and ER-negative/HER2-positive (27.9%) tumors and essentially no effect for ER-positive/HER2-negative (1.3%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.